Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 3, 2004 - Issue 3
Submit an article Journal homepage
140
Views
15
CrossRef citations to date
0
Altmetric
Review

The pharmacology of bipolar disorder during pregnancy and breastfeeding

Seetal Dodd University of Melbourne, Department of Clinical and Biomedical Sciences, University of Melbourne, Community and Mental Health, Barwon Health, Swanston Centre, PO Box 281, Geelong, Victoria 3220, Australia. [email protected]
&
Michael Berk University of Melbourne, Department of Clinical and Biomedical Sciences, University of Melbourne, Community and Mental Health, Barwon Health, Swanston Centre, PO Box 281, Geelong, Victoria 3220, Australia. [email protected]
Pages 221-229 | Published online: 03 Mar 2005

Bibliography

  • VIGUERA AC, COHEN LS: The course and management of bipolar disorder during pregnancy. Psychopharmacol Bull. (1998) 34:339–346.
  • FINNERTY M, LEVIN Z, MILLER LJ: Acute manic episodes in pregnancy. Am.Psychiatry (1996) 153:261–263.
  • GROF P, ROBBINS W, ALDA M et al: Protective effect of pregnancy in women with lithium-responsive bipolar disorder. Affect. Disord. (2000) 61:31–39.
  • VIGUERA AC, NONACS R, COHEN LS et al.: Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am.j Psychiatry (2000) 157:179–184.
  • ••This paper provides evidence to dispel thebelief that pregnancy is protective against mood disturbances.
  • BRATFOS O, HAUG JO: Puerperal mental disorders in manic-depressive females. Acta Psychiatr: Scand. (1966) 42:285–294.
  • REICH T, WINOKUR G: Postpartum psychoses in patients with manic depressive disease. Nerv. Ment. Dis. (1970) 151:60–68.
  • VIGUERA AC, COHEN LS, BALDESSARINI RJ, NONACS R: Managing bipolar disorder during pregnancy: weighing the risks and benefits. Can. Psychiatry (2002) 47:426–436.
  • KENDELL RE, CHALMERS JC, PLATZ C: Epidemiology of puerperal psychoses. Br. Psychiatry (1987) 150:662–673.
  • FREEMAN MP, SMITH KW, FREEMAN SA et al.: The impact of reproductive events on the course of bipolar disorder in women. j. Clin. Psychiatry(2002) 63:284–287.
  • FREEMAN MP, KECK PE Jr, MCELROY SL: Postpartum depression with bipolar disorder. Am. Psychiatry (2001) 158:652.
  • CRUIKSHANK DP WIGTON TR, HAYS PM: Maternal Physiology in Pregnancy. In: Obstetrics: normal and problem pregnancies. Gabbe SG, Niebyl JR, Simpson JL (Eds), Churchill Livingstone, Inc., New York (1996).
  • NEWPORT DJ, WILCOX MM, STOWE ZN: Maternal depression: a child's first adverse life event. Semin. Neumpsychiatry (2002) 7:113–119.
  • HAY DF, PAWLBY S, SHARP D et al: Intellectual problems shown by 11-year-old children whose mothers had postnatal depression. I Child Psycho]. Psychiatry (2001) 42:871–889.
  • KURSTJENS S, WOLKE D: Effects of maternal depression on cognitive development of children over the first 7 years of life. J. Child Psycho]. Psychiatry (2001) 42:623–636.
  • MURRAY L, COOPER P: Effects of postnataldepression on infant development. Arch. Dis. Child (1997) 77:99–101.
  • UAUY R, DE ANDRACA I: Human milk and breast feeding for optimal mental development. Nuti: (1995) 125:S2278–S2280.
  • MARKOVITZ PJ, CALABRESE JR: Use of anticonvulsants for manic depression during pregnancy. Psychosomatics (1990) 31:118.
  • SCHOU M, GOLDFIELD MD, WEINSTEIN MR, VILLENEUVE A: Lithium and pregnancy. I. Report from the Register of Lithium Babies. Br. Med. (1973) 2:135–136.
  • COHEN LS, FRIEDMAN JM, JEFFERSON JW, JOHNSON EM, WEINER ML: A reevaluation of risk of in utero exposure to lithium. JAM (1994) 271:146–150.
  • ••Recalculates the risk of in Moro exposure tolithium to be less than previously thought.
  • ERNST CL, GOLDBERG JF: The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. Clin. Psychiatry (2002) 63\(Suppl. 4):42–55.
  • FRASSETTO F, TOURNEUR MARTEL F, BARJHOUX CE, VILLIER C, BOT BL, VINCENT F: Goiter in a newborn exposed to lithium in utero. Ann. Pharmacother: (2002) 36:1745–1748.
  • IQBAL MM, SOHHAN T, MAHMUD SZ: The effects of lithium, valproic acid, and carbamazepine during pregnancy and lactation. Toxicol Clin. Toxicol (2001) 39:381–392.
  • IQBAL MM, GUNDLAPALLI SP, RYAN WG, RYALS T, PASSMAN TE: Effects of antimanic mood-stabilizing drugs on fetuses, neonates, and nursing infants. South. Med. (2001) 94:304–322.
  • JACOBSON SJ, JONES K, JOHNSON K et al: Prospective multi-centre study of pregnancy outcome after lithium exposure during first trimester. Lancet (1992) 339:530–533.
  • •Gives the outcomes for 138 pregnancies.
  • KALLEN B, TANDBERG A: Lithium and pregnancy. A cohort study on manic-depressive women. Ada Psychiatr. Scand. (1983) 68:134–139.
  • ARNON RG, MARIN-GARCIA J, PEEDEN JN: Tricuspid valve regurgitation and lithium carbonate toxicity in a newborn infant. Am. Dis. Child (1981) 135:941–943.
  • WILSON N, FORFAR JD, GODMAN MJ: Atrial flutter in the newborn resulting from maternal lithium ingestion. Arch. Dis. Child (1983) 58:538–539.
  • KARLSSON K, LINDSTEDT G, LUNDBERG PA, SELSTAM U: Letter: Transplacental lithium poisoning: reversible inhibition of fetal thyroid. Lancet (1975) 1:1295.
  • MIZRAHI EM, HOBBS JF, GOLDSMITH DI: Nephrogenic diabetes insipidus in transplacental lithium intoxication. Pediatr. (1979) 94:493–495.
  • PINELLI JM, SYMINGTON AJ, CUNNINGHAM KA, PAES BA: Case report and review of the perinatal implications of maternal lithium use. Am. Obstet. Cynecol (2002) 187:245–249.
  • MORRELL P, SUTHERLAND GR, BUAMAH PK, OO M, BAIN HH: Lithium toxicity in a neonate. Arch. Dis. Child. (1983) 58:539–541.
  • YODER MC, BELIK J, LANNON RA, PEREIRA GR: Infants of mothers treated with lithium during pregnancy have an increased incidence of prematurity, macrosomia and perinatal mortality. Pediatr. Res. (1984) 18:163A.
  • WOODY JN, LONDON WL, WILBANKS GD Jr: Lithium toxicity in a newborn. Pediatrics (1971) 47:94–96.
  • LLEWELLYN A, STOWE ZN, STRADER JR Jr: The use of lithium and management of women with bipolar disorder during pregnancy and lactation. Cliff Psychiatry (1998) 59\(Suppl. 6):57–64. Discussion 65.
  • KRAMER A, KNOPPERT-VAN DER KLEIN EAM, VAN KAMP IL et al: Bipolar and pregnant? No problem! A clinical evaluation of lithium use during pregnancy. Eur. Neuropsychopharmacol (2003) 13:S246.
  • WILLIAMS K, OKE S: Lithium and pregnancy. Psychiam Bull. (2000) 24:229–231.
  • LICHT RW, VESTERGAARD P, KESSING LV, LARSEN JK, THOMSEN PH: Psychopharmacological treatment with lithium and antiepileptic drugs: suggested guidelines from the Danish Psychiatric Association and the Child and Adolescent Psychiatric Association in Denmark. Acta Psychiam Scand. Sapp]. (2003) 419:1–22.
  • •A useful and practical set of guidelines.
  • SCHOU M, AMDISEN A: Lithium and pregnancy. 3. Lithium ingestion by children breast-fed by women on lithium treatment. Br. Med. J. (1973) 2:138.
  • SCHOU M, AMDISEN A, STEENSTRUP OR: Lithium and pregnancy. II. Hazards to women given lithium during pregnancy and delivery. Br. Med. J. (1973) 2:137–138.
  • WEINBAUM PJ, CASSIDY SB, VINTZILEOS AM et al: Prenatal detection of a neural tube defect after fetal exposure to valproic acid. Obstet. Gynecol (1986) 67:S31–S33.
  • ROBERT E, GUIBAUD P: Maternal valproic acid and congenital neural tube defects. Lancet (1982) 2:937.
  • LINDHOUT D, MEINARDI H: Spina bifida and M utero exposure to valproate. Lancet (1984) 2:396.
  • PIPPENGER CE: Pharmacology of neuraltube defects. Epilepsia (2003) 44\(Suppl. 3):24–32.
  • KAO J, BROWN NA, SCHMID B, GOULDING EH, FABRO S: Teratogenicity of valproic acid: in vivo and in vitro investigations. 7eratog. Carcinog. Mutagen. (1981) 1:367–382.
  • MAST TJ, CUKIERSKI MA, NAU H, HENDRICKX AG: Predicting the human teratogenic potential of the anticonvulsant, valproic acid, from a non-human primate model. Toxicology (1986) 39:111–119.
  • KOCH S, JAGER-ROMAN E, RATING D, HELGE H: Possible teratogenic effect of valproate during pregnancy. Pediatr. (1983) 103:1007–1008.
  • MCMAHON CL, BRADDOCK SR: Septo-optic dysplasia in a child exposed to valproic acid M utero. Teratology (1998) 57:284.
  • THISTED E, EBBESEN F: Malformations, withdrawal manifestations, and hypoglycaemia after exposure to valproate in utero. Arch. Dis. Child (1993) 69:288–291.
  • WINTER RM, DONNAI D, BURN J, TUCKER SM: Fetal valproate syndrome: is there a recognisable phenotype? J. Med. Genet. (1987) 24:692–695.
  • DILIBERTI JH, FARNDON PA, DENNIS NR, CURRY CJ: The fetal valproate syndrome. Am.j Med. Genet. (1984) 19:473–481.
  • •A description of the fetal valproate syndrome, which includes seven case reports.
  • ARDINGER HH, ATKIN JF, BLACKSTON RD et al: Verification of the fetal valproate syndrome phenotype. Am. J. Med. Genet. (1988) 29:171–185.
  • RODRIGUEZ-PINILLA E, ARROYO I, FONDE VILLA J, GARCIA MJ, MARTINEZ-FRIAS ML: Prenatal exposure to valproic acid during pregnancy and limb deficiencies: a case-control study. Am. Med. Genet. (2000) 90:376–381.
  • BASON L, MING JE, ZACKAL EH: Intrauterine hemorrhage associated with prenatal valproate exposure. Jim. .1 Hum. Genet. (1998) 63:A159.
  • MAJER RV, GREEN PJ: Neonatal afibrinogenaemia due to sodium valproate. Lancet (1987) 2:740–741.
  • LEGIUS E, JAEKEN J, EGGERMONT E: Sodium valproate, pregnancy, and infantile fatal liver failure. Lancet (1987) 2:1518–1519.
  • STAHL MM, NEIDERUD J, VINGE E: Thrombocytopenic purpura and anemia in a breast-fed infant whose mother was treated with valproic acid. Pediatr. (1997) 130:1001–1003.
  • TSURU N, MAEDA T, TSURUOKA M: Three cases of delivery under sodium valproate-placental transfer, milk transfer and probable teratogenicity of sodium valproate. fpn. J. Psychiatry Nemo]. (1988) 42:89–96.
  • CHAUDRON LH, JEFFERSON JW: Mood stabilizers during breastfeeding: a review. Clin. Psychiatry (2000) 61:79–90.
  • PIONTEK CM, BAAB S, PEINDL KS, WISNER KL: Serum valproate levels in 6 breastfeeding mother-infant pairs. Clin. Psychiatry (2000) 61:170–172.
  • IQBAL MM: Prevention of neural tube defects by periconceptional use of folic acid. Pediatr. Rev (2000) 21:58-66; quiz 66.
  • FREY L, HAUSER WA: Epidemiology of neural tube defects. Epilepsia (2003) 44\(Suppl. 3):4–13.
  • YERBY MS: Clinical care of pregnant women with epilepsy: neural tube defects and folic acid supplementation. Epilepsia (2003) 44\(Suppl. 3):33–40.
  • KAAJA E, KAAJA R, MATILA R, HIILESMAA V: Enzyme-inducing antiepileptic drugs in pregnancy and the risk of bleeding in the neonate. Neurology(2002) 58:549–553.
  • BAPTISTA T, ARAUJO H, RADA P, HERNANDEZ L: Congenital neuroblastoma in a boy born to a woman with bipolar disorder treated with carbamazepine during pregnancy. Ping. Neuropsychopharmacol Biol. Psychiatry (1998) 22:445–454.
  • FREY B, SCHUBIGER G, MUSY JP: Transient cholestatic hepatitis in a neonate associated with carbamazepine exposure during pregnancy and breast-feeding. Eur.j Pediatr. (1990) 150:136–138.
  • MERLOB P, MOR N, LIT WIN A: Transient hepatic dysfunction in an infant of an epileptic mother treated with carbamazepine during pregnancy and breastfeeding. Ann. Pharmacothec (1992) 26:1563–1565.
  • LINDHOUT D, HOPPENER RJ, MEINARDI H: Teratogenicity of antiepileptic drug combinations with special emphasis on epoxidation (of carbamazepine). Epilepsia (1984) 25:77–83.
  • JONES KL, LACRO RV, JOHNSON KA, ADAMS J: Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N. Engl. J. Med. (1989) 320:1661–1666.
  • •An important evaluation of the teratogenicity of carbamazepine.
  • ROSA FW: Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl. J. Med. (1991) 324:674–677.
  • LITTLE BB, SANTOS-RAMOS R, NEWELL JF, MABERRY MC: Megadose carbamazepine during the period of neural tube closure. Obstet. Gynecol (1993) 82:705–708.
  • PYNNONEN S, KANTO J, SILLANPAA M, ERKKOLA R: Carbamazepine: placental transport, tissue concentrations in foetus and newborn, and level in milk. Acta Pharmacol Toxicol (Copenh) (1977) 41:244–253.
  • NIEBYL JR, BLAKE DA, FREEMAN JM,LUFF RD: Carbamazepine levels in pregnancy and lactation. Obstet. Cynecol (1979) 53:139–140.
  • BRENT NB, WISNER KL: Fluoxetine and carbamazepine concentrations in a nursing mother/infant pair. Clin. Pediatr. (Phila.) (1998) 37:41–44.
  • BERK M, DODD S: Recent developmentsin the treatment of bipolar disorders. Expert Opin. Investig. Drugs (2003) 12:1621–1632.
  • •An extensive review.
  • MORRELL MJ: The new antiepileptic drugs and women: efficacy, reproductive health, pregnancy, and fetal outcome. Epilepsia (1996) 37\(Suppl. 6):S34–S44.
  • RAMBECK B, KURLEMANN G, STODIECK SR, MAY TW, JURGENS U: Concentrations of lamotrigine in a mother on lamotrigine treatment and her newborn child. Eur. Clin. Pharmacol (1997) 51:481–484.
  • OHMAN I, VITOLS S, TOMSON T: Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia (2000) 41:709–713.
  • PENNELL PB: Antiepileptic drug pharmacokinetics during pregnancy and lactation. Neurology (2003) 61:S35–S42.
  • MYLLYNEN P, PIENIMAKI P, JOUPPILA P, VAHAKANGAS K: Transplacental passage of oxcarbazepine and its metabolites in vivo. Epilepsia (2001) 42:1482–1485.
  • PIENIMAKI P, LAMPELA E, HAKKOLAJ et al.: Pharmacokinetics of oxcarbazepine and carbamazepine in human placenta. Epilepsia (1997) 38:309–316.
  • MAY TW, KORN-MERKER E, RAMBECK B: Clinical pharmacokinetics of oxcarbazepine. Clin. Pharmacokinet. (2003) 42:1023–1042.
  • GUILLE C, SACHS GS, GHAEMI SN: A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. J. Gin. Psychiatry (2000) 61:638–642.
  • KETTER TA, TOHEN M, VIETA E et al:Open-label maintenance treatment for bipolar depression using olanzapine or olanzapine/fluoxetine combination. 43rd Annual NCDEU Conference. 27–30 May 2003, Boca Raton, Florida, USA (2003).
  • TOHEN M, VIETA E, CALABRESE JR et al.: Olanzapine/fluoxetine combination and olanzapine in the treatment of bipolar depression. American Psychiatric Association 156th Annual Meeting.17-22 May 2003, San Francisco, USA (2003).
  • TOHEN M, SANGER TM, MCELROY SL et al: Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am. J. Psychiatry(1999) 156:702–709.
  • TOHEN M, BAKER RW, ALTSHULER LL et al.: Olanzapine versus divalproex in the treatment of acute mania. Am. J. Psychiatry (2002) 159:1011–1017.
  • TOHEN M, BOWDEN CL, CALABRESE JR et al.: Olanzapine's efficacy for relapse prevention in bipolar disorder: a randomized double-blind, placebo-controlled 12-month clinical trial. Bipolar Disord. (2003) 5:89.
  • KECK PE Jr, VERSIANI M, POTKIN S et al.: Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am. J. Psychiatry (2003) 160:741–748.
  • KECK PE Jr, MARCUS R, TOURKODIMITRIS S et al: A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am. J. Psychiatry (2003) 160:1651–1658.
  • ADITYANJEE, SCHULZ SC: Clinical use of quetiapine in disease states other than schizophrenia. I Gin. Psychiatry (2002) 63\(Suppl. 13):32–38.
  • PATTON SW, MISRI S, CORRAL MR, PERRY KF, KUAN AJ: Antipsychotic medication during pregnancy and lactation in women with schizophrenia: evaluating the risk. Can. J. Psychiatry (2002) 47:959–965.
  • GOLDSTEIN DJ, CORBIN LA, FUNG MC: Olanzapine-exposed pregnancies and lactation: early experience. Chu. Psychopharmacol (2000) 20:399–403.
  • SCHENKER S, YANG Y, MATTIUZ E, TATUM D, LEE M: Olanzapine transfer by human placenta. Gin. Exp. Pharmacol Physic] (1999) 26:691–697.
  • GARDINER SJ, KRISTENSEN JH, BEGG EJ et al.: Transfer of olanzapine into breast milk, calculation of infant drug dose, and effect on breast-fed infants. Am.). Psychiatry (2003) 160:1428–1431.
  • TENYI T, TRIXLER M, KERESZTES Z: Quetiapine and pregnancy. Am. I Psychiatry (2002) 159:674.
  • NONACS R, COHEN LS: Assessment and treatment of depression during pregnancy: an update. Psychiatr. Chu. North Am. (2003) 26:547–562.
  • DODD S, BUIST A, NORMAN TR: Antidepressants and breast-feeding: a review of the literature. Paediatr. Drugs (2000) 2:183–192.
  • •An extensive review.
  • EINARSON A, FATOYE B, SARKAR M et al: Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am.). Psychiatry (2001) 158:1728–1730.
  • KULIN NA, PASTUSZAK A, SAGE SR et al: Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA (1998) 279:609–610.

Websites

  • http://mims.hcn.net.au MIMS online version 1.1 (2004). Subscription required.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.